Share on Facebook Share on Twitter Email
Answers.com

cirrhosis

 
(sĭ-rō'sĭs) pronunciation
n.
  1. A chronic disease of the liver characterized by the replacement of normal tissue with fibrous tissue and the loss of functional liver cells. It can result from alcohol abuse, nutritional deprivation, or infection especially by the hepatitis virus.
  2. Chronic interstitial inflammation of any tissue or organ.

[New Latin : Greek kirros, tawny (from the color of the diseased liver) + -OSIS.]

cirrhotic cir·rhot'ic (-rŏt'ĭk) adj.

Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics

Degeneration of functioning liver cells and their replacement with fibrous connective tissue, leading to scarring. The most common cause is alcohol abuse with malnutrition. Others include bile duct obstruction, viral infection, toxins, iron or copper accumulation in liver cells, and syphilis. Jaundice, edema, and great abdominal swelling are common in all. Death usually results from internal bleeding or hepatic coma due to blood chemical imbalance.

For more information on cirrhosis, visit Britannica.com.

A liver disease characterized by a marked increase in fibrous connective tissue, resulting in a firm, nodular, distorted liver.

There are numerous causes of cirrhosis. In the United States the majority of cases are caused by excessive alcohol consumption, and the condition is referred to as alcoholic cirrhosis. Cirrhosis may occur as a result of the healing of severe fulminant hepatitis or chronic active hepatitis. Some cases are caused by obstruction of the bile duct by calculi (stones) and are referred to as secondary biliary cirrhosis. Primary biliary cirrhosis is primarily a disease of middle-aged women and is caused by an autoimmune destruction of bile ducts. Autoimmune hepatitis, sometimes referred to as lupoid hepatitis and characteristically seen in young women and associated with serum autoantibodies, may progress to cirrhosis. Relatively few cases of cirrhosis are caused by genetically determined deficiencies in certain substances. See also Alcoholism; Hepatitis.

The signs and symptoms of cirrhosis are nonspecific and frequently related to the complications. As the liver becomes fibrotic, there is obstruction of the blood flow through the liver. This results in portal hypertension, an increase in blood pressure within the portal vein and its tributaries. The obstructed hepatic blood flow also causes congestion of the spleen, leading to a markedly enlarged spleen (splenomegaly). Also, most people with cirrhosis eventually develop fluid in their abdomen (ascites) and are at an increased risk of developing a spontaneous intraabdominal infection. In addition to obstruction of blood flow, the bile ducts within the liver are distorted and frequently partially obstructed by the increased connective tissue. This results in jaundice, a yellow discoloration of all tissues and organs, including the skin. Some individuals with advanced cirrhosis develop renal failure, a condition referred to as hepatorenal syndrome. Also, there is a definite increase in liver cell cancer in cirrhotic persons. The liver may be slightly enlarged, but as the disease progresses it usually becomes smaller due to progressive loss of liver cells. See also Jaundice.

The therapy of cirrhosis is aimed primarily at preventing or reducing the complications. Bleeding esophageal varices (collateral venous channels) are a frequent serious complication of cirrhosis. Various techniques are used to control the bleeding. In some individuals with severe portal hypertension, vascular shunts are made to reduce the pressure in the portal vein by bypassing the liver. Most frequently the portal vein is surgically connected to the inferior vena cava so that some of the blood in the portal vein does not pass through the liver. See also Cardiovascular system; Liver disorders.


The term "cirrhosis" was first used by René Laënnec (1781–1826) to describe the abnormal liver color of individuals with alcohol-induced liver disease. The word cirrhosis comes from the Greek word kirrhos, the name for a yellowish-brown color.

The human liver is the largest single organ in the body and consists of parenchymal cells, which metabolize, detoxify, synthesize, and store nutrients. Normal functioning of these cells depends on their proper organization. Cirrhosis, the final common pathway for a variety of liver diseases, occurs when excessive fibrosis results in the conversion of normal liver architecture into structurally abnormal nodules. Cirrhosis is irreversible and can be life threatening—it is a public health concern because of its associated mortality and morbidity. The only available and definitive treatment is liver transplantation. Cirrhosis is, however, preventable in most cases.

Prevalence

The exact prevalence of cirrhosis is unknown, but it has been estimated, through autopsies, to be between 5 and 10 percent. Incidence of cirrhosis varies by country and region, and reflects relative contributions from different risk factors. In countries where alcohol consumption is common, alcoholic cirrhosis is the major contributor to the overall prevalence of cirrhosis. In countries with low alcohol consumption, hepatotropic viruses (hepatitis B and C) are the major contributors.

An estimated 25,000 individuals in the United States died from liver disease in 1998, making liver disease the tenth leading cause of death. For individuals between 45 and 64 years of age, chronic liver disease had an associated mortality rate of 19.6 per 100,000 persons and was the seventh leading cause of death. The mortality rate for

Table 1

Common Causes of Cirrhosis
SOURCE: Courtesy of author.
  • Alcohol
  • Viral hepatitis: hepatitis B, hepatitis C
  • Metabolic: alpha-1 antitrypsin deficiency, Wilson's disease, hemochromatosis
  • Cholestatic: primary biliary cirrhosis, primary sclerosing cholangitis

white men between 45 and 64 years of age was 28.2 per 100,000 persons, and cirrhosis was the fourth leading cause of death (in 1998).

Causes of Liver Diseases

Ethanol. Ethanol (alcohol) is the most common cause of cirrhosis in the United States (see Table1). Over three-quarters of Americans drink ethanol. The amount necessary to cause cirrhosis differs based on gender and nutritional status, and the relative risk of alcoholic cirrhosis increases with greater amounts of alcohol consumption. It has been estimated that alcoholic cirrhosis develops in women drinking at least 20 grams of alcohol a day for 5 to 10 years, and in men drinking at least 40 grams per day for the same period. A 12-ounce can of beer, 5-ounce a glass of wine, and a 1.5 ounce shot of hard liquor all contain between 10 and 20 grams of ethanol. Malnutrition and infection with hepatotropic viruses may also increase the risk of cirrhosis.

Compelling epidemiological data indicate a strong association between alcohol consumption and cirrhosis mortality. Between 1906 and 1934, per capita alcohol consumption in the United States dropped from 9.8 liters of absolute alcohol to 3.7 liters. Liver cirrhosis mortality fell from approximately 16 deaths per 100,000 prior to the Prohibition era, to 8 deaths per 100,000 during the Prohibition era and for several decades after Prohibition laws were repealed. Between 1950 and 1973, however, mortality due to cirrhosis rose from 8.5 deaths per 100,000 to 14.9 deaths per 100,000. This increase followed and paralleled an increase in total alcohol consumption. Between 1970 and 1990, although total alcohol consumption remained stable, the mortality rate from cirrhosis decreased. Plausible reasons for this discrepancy include lowering the greater than previously recognized nonalcohol contribution to the overall mortality rate due to cirrhosis and improved behavior regarding alcohol.

Hepatotropic Viruses. Hepatotropic viruses represent the second major category of the causes of cirrhosis. Hepatotropic viruses account for most orthotopic liver transplantations in the United States.

Approximately 4 million people in the United States are believed to be infected by hepatitis C. Prevalence varies considerably by country, e.g., from 0.1 to 2 percent in Europe and North America to 5 to 20 percent in Egypt (see Table 2). Hepatitis C infection results in chronic hepatitis in 85 percent of infected individuals, and in cirrhosis in 20 percent. The mean time progression to hepatic cirrhosis following viral infection is twenty years. Factors associated with progression of hepatitis C-related liver disease include chronic alcoholism and viral coinfection with hepatitis B.

Blood transfusion was the single major risk factor for hepatitis C infection until the early 1990s; today it accounts for a minority of hepatitis C cases because of blood screening for hepatitis C. Illegal drug use now accounts for more than half of the cases of hepatitis C infection, and this proportion is likely to increase in the near future when many individuals infected with hepatitis C in the 1960s and 1970s, largely as a result of sharing needles, seek medical attention.

Public health efforts are best directed at preventing viral hepatitis infection. Once patients are

Table 2

Worldwide Hepatitis C Virus Prevalence
SOURCE: Courtesy of author.
Low prevalence (0.1 to 2%)
Australia
Brazil
Western Europe
North America
Mexico
Russia
Middle East
Intermediate prevalence (2 to 5%)
Parts of South America
Asia
Philippines
High prevalence (5 to 20%)
Egypt

infected, antiviral therapy may eliminate the virus from the blood and prevent the progression to hepatic cirrhosis.

Approximately 1 to 1.25 million Americans are infected with the hepatitis B virus. Worldwide, an estimated 1 to 2 million people die of hepatitis B-associated liver disease annually (see Table 3). The worldwide prevalence varies greatly among countries, from 0.1 to 2 percent in Europe and North America, and from 5 to 20 percent in Southeast Asia and Eastern Europe. It is estimated that 12 to 20 percent of patients with chronic hepatitis B progress to cirrhosis within five years. The risk of hepatitis B infection from a blood transfusion was once up to 50 percent, but it is now exceedingly uncommon, largely as a result of blood screening. The implementation of hepatitis B immunization programs in infants has also contributed to the decreasing number of new cases of hepatitis B infection.

Although the major risk factor for hepatitis B transmission is sexual, the rate has also fallen significantly in recent years because of changes in high-risk sexual behavior. Like hepatitis C, progression to cirrhosis can be halted with antiviral therapy.

Cirrhosis is a major public health concern. The major causes of cirrhosis are mostly related to

Table 3

Worldwide Hepatitis B Virus Prevalence
SOURCE: Courtesy of author.
Low prevalence (0.1 to 2%)
North America
Western Europe
Australia
New Zealand
Parts of South America
Intermediate prevalence (2 to 5%)
Southern and Eastern Europe
Middle East
Western Asia through the Indian subcontinent
Parts of Central and South America
High prevalence (5 to 20%)
Asia east of the Indian subcontinent
Pacific Basin
Amazon Basin
Arctic Rim
Asia Minor
Parts of Eastern Europe
Caribbean

lifestyle behaviors such as alcohol consumption, injectable drug use, and unprotected sex. Public health efforts should focus on programs that address these activities.

(SEE ALSO: Alcohol Use and Abuse; Hepatitis A Vaccine; Hepatitis B Vaccine)

Bibliography

Alter, M. J. (1997). "The Epidemiology of Acute and Chronic Hepatitis C." Clinical Liver Disease 1:559–568.

Garcia, G.; Petrovic, L. M.; and Vierling, J. M. (2000). "Overview of Hepatitis B and Transplantation in the Hepatitis B Patient." Semin Liver Dis 20 (Supp. 1): 3–6.

Giarelli, L.; Melato, M.; Laurino, L.; Peruzzo, P.; Musse, M. M.; and Delendi, M. (1991). "Occurrence of Liver Cirrhosis among Autopsies in Trieste." Internal Agency for Research on Cancer Science Publications 112:37–43.

Graudal, N.; Leth, P.; Marbjerg, L.; and Galloe, A. M. (1991). "Characteristics of Cirrhosis Undiagnosed During Life: A Comparative Analysis of 73 Undiagnosed Cases and 149 Diagnosed Cases of Cirrhosis, Detected in 4929 Consecutive Autopsies." Journal of Internal Medicine 230:165–171.

McCullough, A. J. (1999). "Alcoholic Liver Disease." In Schiff's Diseases of the Liver, 8th edition, eds. E. R. Schiff, M. F. Sorrell, and W. C. Maddrey. Philadelphia, PA: Lippincott-Raven.

Roizen, R.; Kerr, W. C.; and Fillmore, K. M. (1999). "Cirrhosis Mortality and Per Capita Consumption of Distilled Spirits, United States, 1949–94: Trend Analysis." British Medical Journal 319:666–670.

Rothenberg, R. B., and Koplan, J. P. (1990). "Chronic Disease in the 1990s." Annual Review of Public Health 11:267–296.

— SAMMY SAAB; SERGIO E. ROJTER



Columbia Encyclopedia:

cirrhosis

Top
cirrhosis (sərō'səs), degeneration of tissue in an organ resulting in fibrosis, with nodule and scar formation. The term is most often used in relation to the liver, because that organ is most often involved in cirrhosis. Cirrhosis of the liver interferes with the liver's metabolism of nutrients, detoxification of the blood, bile production, and other normal functions (see liver); its damage is irreversible.

The most prevalent form of cirrhosis of the liver, portal cirrhosis, appears most often in middle-aged males with a history of chronic alcoholism and is caused in part by protein deficiency (specifically choline), a type of malnutrition common in alcoholics. Protein deprivation is also responsible for kwashiorkor, a nutritional deficiency with symptoms resembling those of cirrhosis of the liver. A major cause of cirrhosis worldwide is infection by the hepatitis B virus. Biliary cirrhosis is a type caused by disruption of bile flow and is more common in women. Other causes include schistosomiasis and hemochromatosis, a hereditary iron storage disease.

Failure of liver function results in ascites (fluid accumulation in the abdominal cavity), increased albumin and blood protein, gastrointestinal disturbances, bleeding, emaciation, portal hypertension, enlargement of the liver and spleen, jaundice, edema, and obstruction of the venous circulation with distention of the veins. It is not uncommon for greatly distended veins in the esophagus to rupture and cause massive hemorrhage. Treatment is first aimed at any reversible underlying disease. Supportive measures include avoidance of alcohol, a diet with adequate protein, vitamin supplements, transfusions to replace any blood loss, and removal of accumulated fluid. Beta-blockers, such as propranolol, have been shown to be effective in reducing the rate of gastrointestinal bleeding, one of the most lethal complications of cirrhosis.


(suh-roh-sis)

A chronic disease of the liver, characterized by replacement of normal liver cells with a form of connective tissue. Owing to the scarring caused by this disease, irreversible damage to the liver can result.

  • Cirrhosis is often associated with alcoholism.

  • A liver disease characterized pathologically by the loss of the normal microscopic lobular architecture and regenerative replacement of necrotic parenchymal tissue with fibrous bands of connective tissue which eventually constrict and partition the organ into irregular nodules. The term is sometimes used to refer to chronic interstitial inflammation of any organ.

    • cardiac c. — fibrosis or scarring of the liver resulting from the anoxia and centrilobular necrosis associated with the passive congestion of congestive heart failure.

    n

    A chronic degenerative disease of the liver in which blood flow is restricted and metabolic and detoxification functions are impaired or destroyed. Cirrhosis is most commonly the result of chronic alcohol abuse.

    Random House Word Menu:

    categories related to 'cirrhosis'

    Top
    Random House Word Menu by Stephen Glazier
    For a list of words related to cirrhosis, see:
    • Diseases and Infestations - cirrhosis: progressive liver condition from various causes, esp. alcoholism or hepatitis, in which cells die and the liver turns tawny and knobby


    Cirrhosis
    Classification and external resources

    The abdomen of a person with cirrhosis showing massive ascites and caput medusae
    ICD-10 K70.3, K71.7, K74
    ICD-9 571
    DiseasesDB 2729
    eMedicine med/3183 radio/175
    MeSH D008103

    Cirrhosis (play /sɪˈrsɪs/) is a consequence of chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue and regenerative nodules (lumps that occur as a result of a process in which damaged tissue is regenerated),[1][2][3] leading to loss of liver function. Cirrhosis is most commonly caused by alcoholism, hepatitis B and C, and fatty liver disease, but has many other possible causes. Some cases are idiopathic, i.e., of unknown cause.

    Ascites (fluid retention in the abdominal cavity) is the most common complication of cirrhosis, and is associated with a poor quality of life, increased risk of infection, and a poor long-term outcome. Other potentially life-threatening complications are hepatic encephalopathy (confusion and coma) and bleeding from esophageal varices. Cirrhosis is generally irreversible, and treatment usually focuses on preventing progression and complications. In advanced stages of cirrhosis the only option is a liver transplant.

    The word "cirrhosis" derives from Greek κιρρός [kirrhós] meaning yellowish, tawny (the orange-yellow colour of the diseased liver) + Eng. med. suff. -osis. While the clinical entity was known before, it was René Laennec who gave it the name "cirrhosis" in his 1819 work in which he also describes the stethoscope.[4]

    Contents

    Signs and symptoms

    Some of the following signs and symptoms may occur in the presence of cirrhosis or as a result of the complications of cirrhosis. Many are nonspecific and may occur in other diseases and do not necessarily point to cirrhosis. Likewise, the absence of any does not rule out the possibility of cirrhosis.

    • Spider angiomata or spider nevi. Vascular lesions consisting of a central arteriole surrounded by many smaller vessels because of an increase in estradiol. These occur in about 1/3 of cases.[5]
    • Palmar erythema. Exaggerations of normal speckled mottling of the palm, because of altered sex hormone metabolism.
    • Nail changes.
      • Muehrcke's lines - paired horizontal bands separated by normal color resulting from hypoalbuminemia (inadequate production of albumin).
      • Terry's nails - proximal two-thirds of the nail plate appears white with distal one-third red, also due to hypoalbuminemia
      • Clubbing - angle between the nail plate and proximal nail fold > 180 degrees
    • Hypertrophic osteoarthropathy. Chronic proliferative periostitis of the long bones that can cause considerable pain.
    • Dupuytren's contracture. Thickening and shortening of palmar fascia that leads to flexion deformities of the fingers. Thought to be caused by fibroblastic proliferation and disorderly collagen deposition. It is relatively common (33% of patients).
    • Gynecomastia. Benign proliferation of glandular tissue of male breasts presenting with a rubbery or firm mass extending concentrically from the nipples. This is caused by increased estradiol and can occur in up to 66% of patients.
    • Hypogonadism. Manifested as impotence, infertility, loss of sexual drive, and testicular atrophy because of primary gonadal injury or suppression of hypothalamic or pituitary function.
    • Liver size. Can be enlarged, normal, or shrunken.
    • Splenomegaly (increase in size of the spleen). Caused by congestion of the red pulp as a result of portal hypertension.
    • Ascites. Accumulation of fluid in the peritoneal cavity giving rise to flank dullness (needs about 1500 mL to detect flank dullness).
    • Caput medusa. In portal hypertension, periumbilical collateral veins may dilate. Blood from the portal venous system may be shunted through the periumbilical veins and ultimately to the abdominal wall veins, manifesting as caput medusa.
    • Cruveilhier-Baumgarten murmur. Venous hum heard in epigastric region (on examination by stethoscope) because of collateral connections between portal system and the periumbilical veins in portal hypertension.
    • Fetor hepaticus. Musty odor in breath as a result of increased dimethyl sulfide.
    • Jaundice. Yellow discoloring of the skin, eye, and mucus membranes because of increased bilirubin (at least 2–3 mg/dL or 30 mmol/L). Urine may also appear dark.
    • Asterixis. Bilateral asynchronous flapping of outstretched, dorsiflexed hands seen in patients with hepatic encephalopathy.
    • Other. Weakness, fatigue, anorexia, weight loss.

    As the disease progresses, complications may develop. In some people, these may be the first signs of the disease.

    • Bruising and bleeding resulting from decreased production of coagulation factors.
    • Jaundice as a result of decreased processing of bilirubin.
    • Itching (pruritus) because of bile salt products deposited in the skin.
    • Hepatic encephalopathy - the liver does not clear ammonia and related nitrogenous substances from the blood, which are carried to the brain, affecting cerebral functioning: neglect of personal appearance, unresponsiveness, forgetfulness, trouble concentrating, or changes in sleep habits.
    • Sensitivity to medication caused by decreased metabolism of the active compounds.
    • Hepatocellular carcinoma is primary liver cancer, a frequent complication of cirrhosis. It has a high mortality rate.
    • Portal hypertension - blood normally carried from the intestines and spleen through the hepatic portal vein flows more slowly and the pressure increases; this leads to the following complications:
      • Ascites - fluid leaks through the vasculature into the abdominal cavity.
      • Esophageal varices - collateral portal blood flow through vessels in the stomach and esophagus (Portacaval anastomosis). These blood vessels may become enlarged and are more likely to burst.
    • Problems in other organs.

    Causes

    Cirrhosis has many possible causes; sometimes more than one cause is present in the same patient. In the Western World, chronic alcoholism and hepatitis C are the most common causes.

    • Alcoholic liver disease (ALD). Alcoholic cirrhosis develops for between 10% and 20% of individuals who drink heavily for a decade or more.[8] Alcohol seems to injure the liver by blocking the normal metabolism of protein, fats, and carbohydrates. Patients may also have concurrent alcoholic hepatitis with fever, hepatomegaly, jaundice, and anorexia. AST and ALT are both elevated but less than 300 IU/L with a AST:ALT ratio > 2.0, a value rarely seen in other liver diseases. Liver biopsy may show hepatocyte necrosis, Mallory bodies, neutrophilic infiltration with perivenular inflammation.
    • Non-alcoholic steatohepatitis (NASH). In NASH, fat builds up in the liver and eventually causes scar tissue. This type of hepatitis appears to be associated with diabetes, protein malnutrition, obesity, coronary artery disease, and treatment with corticosteroid medications. This disorder is similar to that of alcoholic liver disease but patient does not have an alcohol history. Biopsy is needed for diagnosis.
    • Chronic hepatitis C. Infection with the hepatitis C virus causes inflammation of the liver and a variable grade of damage to the organ that over several decades can lead to cirrhosis. Cirrhosis caused by hepatitis C is the most common reason for liver transplant. Can be diagnosed with serologic assays that detect hepatitis C antibody or viral RNA. The enzyme immunoassay, EIA-2, is the most commonly used screening test in the US.
    • Chronic hepatitis B. The hepatitis B virus causes liver inflammation and injury that over several decades can lead to cirrhosis. Hepatitis D is dependent on the presence of hepatitis B and accelerates cirrhosis in co-infection. Chronic hepatitis B can be diagnosed with detection of HBsAG > 6 months after initial infection. HBeAG and HBV DNA are determined to assess whether patient will need antiviral therapy.
    • Primary biliary cirrhosis. May be asymptomatic or complain of fatigue, pruritus, and non-jaundice skin hyperpigmentation with hepatomegaly. There is prominent alkaline phosphatase elevation as well as elevations in cholesterol and bilirubin. Gold standard diagnosis is antimitochondrial antibodies with liver biopsy as confirmation if showing florid bile duct lesions. It is more common in women.
    • Primary sclerosing cholangitis. PSC is a progressive cholestatic disorder presenting with pruritus, steatorrhea, fat soluble vitamin deficiencies, and metabolic bone disease. There is a strong association with inflammatory bowel disease (IBD), especially ulcerative colitis. Diagnosis is best with contrast cholangiography showing diffuse, multifocal strictures and focal dilation of bile ducts, leading to a beaded appearance. Non-specific serum immunoglobulins may also be elevated.
    • Autoimmune hepatitis. This disease is caused by the immunologic damage to the liver causing inflammation and eventually scarring and cirrhosis. Findings include elevations in serum globulins, especially gamma globulins. Therapy with prednisone and/or azathioprine is beneficial. Cirrhosis due to autoimmune hepatitis still has 10-year survival of 90%+. There is no specific tool to diagnose autoimmune but it can be beneficial to initiate a trial of corticosteroids.
    • Hereditary hemochromatosis. Usually presents with family history of cirrhosis, skin hyperpigmentation, diabetes mellitus, pseudogout, and/or cardiomyopathy, all due to signs of iron overload. Labs will show fasting transferrin saturation of > 60% and ferritin > 300 ng/mL. Genetic testing may be used to identify HFE mutations. If these are present, biopsy may not need to be performed. Treatment is with phlebotomy to lower total body iron levels.
    • Wilson's disease. Autosomal recessive disorder characterized by low serum ceruloplasmin and increased hepatic copper content on liver biopsy. May also have Kayser-Fleischer rings in the cornea and altered mental status.
    • Alpha 1-antitrypsin deficiency (AAT). Autosomal recessive disorder. Patients may also have COPD, especially if they have a history of tobacco smoking. Serum AAT levels are low. Recombinant AAT is used to prevent lung disease due to AAT deficiency.
    • Cardiac cirrhosis. Due to chronic right sided heart failure which leads to liver congestion.
    • Galactosemia
    • Glycogen storage disease type IV
    • Cystic fibrosis
    • Hepatotoxic drugs or toxins
    • Lysosomal acid lipase deficiency (LAL Deficiency) is a rare autosomal recessive genetic condition and is characterized by hepatomegaly, persistently abnormal LFTs and type II hyperlipidemia. Splenomegaly and evidence of mild hypersplenism may affect some patients. Untreated, LAL Deficiency may lead to fibrosis, cirrhosis, liver failure and death.

    Pathophysiology

    The liver plays a vital role in synthesis of proteins (e.g., albumin, clotting factors and complement), detoxification and storage (e.g., vitamin A). In addition, it participates in the metabolism of lipids and carbohydrates.

    Cirrhosis is often preceded by hepatitis and fatty liver (steatosis), independent of the cause. If the cause is removed at this stage, the changes are still fully reversible.

    The pathological hallmark of cirrhosis is the development of scar tissue that replaces normal parenchyma, blocking the portal flow of blood through the organ and disturbing normal function. Recent research shows the pivotal role of the stellate cell, a cell type that normally stores vitamin A, in the development of cirrhosis. Damage to the hepatic parenchyma leads to activation of the stellate cell, which becomes contractile (called myofibroblast) and obstructs blood flow in the circulation. In addition, it secretes TGF-β1, which leads to a fibrotic response and proliferation of connective tissue. Furthermore, it secretes TIMP 1 and 2, naturally occurring inhibitors of matrix metalloproteinases, which prevents them from breaking down fibrotic material in the extracellular matrix.[9]

    The fibrous tissue bands (septa) separate hepatocyte nodules, which eventually replace the entire liver architecture, leading to decreased blood flow throughout. The spleen becomes congested, which leads to hypersplenism and increased sequestration of platelets. Portal hypertension is responsible for most severe complications of cirrhosis.

    Diagnosis

    Micrograph showing cirrhosis. Trichrome stain.

    The gold standard for diagnosis of cirrhosis is a liver biopsy, through a percutaneous, transjugular, laparoscopic, or fine-needle approach. A biopsy is not necessary if the clinical, laboratory, and radiologic data suggests cirrhosis. Furthermore, there is a small but significant risk to liver biopsy, and cirrhosis itself predisposes for complications due to liver biopsy.[10]

    Lab findings

    The following findings are typical in cirrhosis:

    • Aminotransferases - AST and ALT are moderately elevated, with AST > ALT. However, normal aminotransferases do not preclude cirrhosis.
    • Alkaline phosphatase - usually slightly elevated.
    • Gamma-glutamyl transferase – correlates with AP levels. Typically much higher in chronic liver disease from alcohol.
    • Bilirubin - may elevate as cirrhosis progresses.
    • Albumin - levels fall as the synthetic function of the liver declines with worsening cirrhosis since albumin is exclusively synthesized in the liver
    • Prothrombin time - increases since the liver synthesizes clotting factors.
    • Globulins - increased due to shunting of bacterial antigens away from the liver to lymphoid tissue.
    • Serum sodium - hyponatremia due to inability to excrete free water resulting from high levels of ADH and aldosterone.
    • Thrombocytopenia - due to both congestive splenomegaly as well as decreased thrombopoietin from the liver. However, this rarely results in platelet count < 50,000/mL.
    • Leukopenia and neutropenia - due to splenomegaly with splenic margination.
    • Coagulation defects - the liver produces most of the coagulation factors and thus coagulopathy correlates with worsening liver disease.

    There is now a validated and patented combination of 6 of these markers as non-invasive biomarker of fibrosis (and so of cirrhosis) : FibroTest.[11]

    Other laboratory studies performed in newly diagnosed cirrhosis may include:

    Imaging

    Liver cirrhosis as seen on an axial CT of the abdomen.

    Ultrasound is routinely used in the evaluation of cirrhosis, where it may show a small and nodular liver in advanced cirrhosis along with increased echogenicity with irregular appearing areas. Ultrasound may also screen for hepatocellular carcinoma, portal hypertension and Budd-Chiari syndrome (by assessing flow in the hepatic vein).

    A new type of device, the FibroScan (transient elastography), uses elastic waves to determine liver stiffness which theoretically can be converted into a liver score based on the METAVIR scale. The FibroScan produces an ultrasound image of the liver (from 20–80 mm) along with a pressure reading (in kPa.) The test is much faster than a biopsy (usually last 2.5–5 minutes) and is completely painless. It shows reasonable correlation with the severity of cirrhosis.[12]

    Other tests performed in particular circumstances include abdominal CT and liver/bile duct MRI (MRCP).

    Endoscopy

    Gastroscopy (endoscopic examination of the esophagus, stomach and duodenum) is performed in patients with established cirrhosis to exclude the possibility of esophageal varices. If these are found, prophylactic local therapy may be applied (sclerotherapy or banding) and beta blocker treatment may be commenced.

    Rarely diseases of the bile ducts, such as primary sclerosing cholangitis, can be causes of cirrhosis. Imaging of the bile ducts, such as ERCP or MRCP (MRI of biliary tract and pancreas) can show abnormalities in these patients, and may aid in the diagnosis.

    Pathology

    Cirrhosis leading to hepatocellular carcinoma (autopsy specimen).

    Macroscopically, the liver is initially enlarged, but with progression of the disease, it becomes smaller. Its surface is irregular, the consistency is firm and the color is often yellow (if associates steatosis). Depending on the size of the nodules there are three macroscopic types: micronodular, macronodular and mixed cirrhosis. In micronodular form (Laennec's cirrhosis or portal cirrhosis) regenerating nodules are under 3 mm. In macronodular cirrhosis (post-necrotic cirrhosis), the nodules are larger than 3 mm. The mixed cirrhosis consists in a variety of nodules with different sizes.

    However, cirrhosis is defined by its pathological features on microscopy: (1) the presence of regenerating nodules of hepatocytes and (2) the presence of fibrosis, or the deposition of connective tissue between these nodules. The pattern of fibrosis seen can depend upon the underlying insult that led to cirrhosis; fibrosis can also proliferate even if the underlying process that caused it has resolved or ceased. The fibrosis in cirrhosis can lead to destruction of other normal tissues in the liver: including the sinusoids, the space of Disse, and other vascular structures, which leads to altered resistance to blood flow in the liver and portal hypertension.[13]

    As cirrhosis can be caused by many different entities which injure the liver in different ways, different cause-specific patterns of cirrhosis, and other cause-specific abnormalities can be seen in cirrhosis. For example, in chronic hepatitis B, there is infiltration of the liver parenchyma with lymphocytes;[13] in cardiac cirrhosis there are erythrocytes and a greater amount of fibrosis in the tissue surrounding the hepatic veins;[14] in primary biliary cirrhosis, there is fibrosis around the bile duct, the presence of granulomas and pooling of bile;[15] and in alcoholic cirrhosis, there is infiltration of the liver with neutrophils.[13]

    Grading

    The severity of cirrhosis is commonly classified with the Child-Pugh score. This score uses bilirubin, albumin, INR, presence and severity of ascites and encephalopathy to classify patients in class A, B or C; class A has a favourable prognosis, while class C is at high risk of death. It was devised in 1964 by Child and Turcotte and modified in 1973 by Pugh et al..[16]

    More modern scores, used in the allocation of liver transplants but also in other contexts, are the Model for End-Stage Liver Disease (MELD) score and its pediatric counterpart, the Pediatric End-Stage Liver Disease (PELD) score.

    The hepatic venous pressure gradient, i.e., the difference in venous pressure between afferent and efferent blood to the liver, also determines severity of cirrhosis, although hard to measure. A value of 16 mm or more means a greatly increased risk of dying.[17]

    Management

    Generally, liver damage from cirrhosis cannot be reversed, but treatment could stop or delay further progression and reduce complications. A healthy diet is encouraged, as cirrhosis may be an energy-consuming process. Close follow-up is often necessary. Antibiotics will be prescribed for infections, and various medications can help with itching. Laxatives, such as lactulose, decrease risk of constipation; their role in preventing encephalopathy is limited.

    Alcoholic cirrhosis caused by alcohol abuse is treated by abstaining from alcohol. Treatment for hepatitis-related cirrhosis involves medications used to treat the different types of hepatitis, such as interferon for viral hepatitis and corticosteroids for autoimmune hepatitis. Cirrhosis caused by Wilson's disease, in which copper builds up in organs, is treated with chelation therapy (e.g., penicillamine) to remove the copper.

    Preventing further liver damage

    Regardless of underlying cause of cirrhosis, alcohol and paracetamol, as well as other potentially damaging substances, are discouraged. Vaccination of susceptible patients should be considered for Hepatitis A and Hepatitis B.

    Transplantation

    If complications cannot be controlled or when the liver ceases functioning, liver transplantation is necessary. Survival from liver transplantation has been improving over the 1990s, and the five-year survival rate is now around 80%, depending largely on the severity of disease and other medical problems in the recipient.[18] In the United States, the MELD score is used to prioritize patients for transplantation.[19] Transplantation necessitates the use of immune suppressants (cyclosporine or tacrolimus).

    Decompensated cirrhosis

    In patients with previously stable cirrhosis, decompensation may occur due to various causes, such as constipation, infection (of any source), increased alcohol intake, medication, bleeding from esophageal varices or dehydration. It may take the form of any of the complications of cirrhosis listed above.

    Patients with decompensated cirrhosis generally require admission to hospital, with close monitoring of the fluid balance, mental status, and emphasis on adequate nutrition and medical treatment - often with diuretics, antibiotics, laxatives and/or enemas, thiamine and occasionally steroids, acetylcysteine and pentoxifylline. Administration of saline is generally avoided as it would add to the already high total body sodium content that typically occurs in cirrhosis.

    Complications

    Ascites

    Salt restriction is often necessary, as cirrhosis leads to accumulation of salt (sodium retention). Diuretics may be necessary to suppress ascites. Diuretic options for inpatient treatment include aldosterone antagonists (usually spironolactone) and loop diuretics. Aldosterone antagonists are preferred for patients who can take oral medications and are not in need of an urgent volume reduction, with loop diuretics as additional therapy.[20]

    If a rapid reduction of volume is required, paracentesis is the preferred option. This requires the insertion of a plastic tube into the peritoneal cavity. Human albumin solution is usually given to prevent complications from the rapid reduction. In addition to being more rapid than diuretics, 4-5 liters of paracentesis is more successful in comparison to diuretic therapy.[20]

    Esophageal variceal bleeding

    For portal hypertension, propranolol is a commonly used agent to lower blood pressure over the portal system. In severe complications from portal hypertension, transjugular intrahepatic portosystemic shunting is occasionally indicated to relieve pressure on the portal vein. As this can worsen encephalopathy, it is reserved for those at low risk of encephalopathy, and is generally regarded only as a bridge to liver transplantation or as a palliative measure.

    Hepatic encephalopathy

    High-protein food increases the nitrogen balance, and would theoretically increase encephalopathy; in the past, this was therefore eliminated as much as possible from the diet. Recent studies show that this assumption was incorrect, and high-protein foods are even encouraged to maintain adequate nutrition.[21]

    Hepatorenal syndrome

    The hepatorenal syndrome is defined as a urine sodium less than 10 mmol/L and a serum creatinine > 1.5 mg/dl (or 24 hourcreatinine clearance less than 40 ml/min) after a trial of volume expansion without diuretics.[22]

    Spontaneous bacterial peritonitis

    Cirrhotic patients with ascites are at risk of spontaneous bacterial peritonitis.

    Epidemiology

    Disability-adjusted life year for cirrhosis of the liver per 100,000 inhabitants in 2004.[23]
      no data
      less than 50
      50-100
      100-200
      200-300
      300-400
      400-500
      500-600
      600-700
      700-800
      800-900
      900-1000
      more than 1000

    Cirrhosis and chronic liver disease were the 10th leading cause of death for men and the 12th for women in the United States in 2001, killing about 27,000 people each year.[24] Also, the cost of cirrhosis in terms of human suffering, hospital costs, and lost productivity is high.

    Established cirrhosis has a 10-year mortality of 34-66%, largely dependent on the cause of the cirrhosis; alcoholic cirrhosis has a worse prognosis than primary biliary cirrhosis and cirrhosis due to hepatitis. The risk of death due to all causes is increased twelvefold; if one excludes the direct consequences of the liver disease, there is still a fivefold increased risk of death in all disease categories.[25]

    Little is known on modulators of cirrhosis risk, apart from other diseases that cause liver injury (such as the combination of alcoholic liver disease and chronic viral hepatitis, which may act synergistically in leading to cirrhosis). Studies have recently suggested that coffee consumption may protect against cirrhosis, especially alcoholic cirrhosis.[26]

    References

    1. ^ "Cirrhosis – MayoClinic.com". http://www.mayoclinic.com/print/cirrhosis/DS00373/DSECTION=all&METHOD=print. 
    2. ^ "Liver Cirrhosis". Review of Pathology of the Liver. http://www.meddean.luc.edu/lumen/MedEd/orfpath/cirhosis.htm. 
    3. ^ "Pathology Education: Gastrointestinal". http://www.pathology.vcu.edu/education/gi/lab3.h.html. 
    4. ^ Roguin A (2006). "Rene Theophile Hyacinthe Laënnec (1781–1826): The Man Behind the Stethoscope". Clinical medicine & research 4 (3): 230–5. doi:10.3121/cmr.4.3.230. PMC 1570491. PMID 17048358. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1570491. 
    5. ^ Li CP, Lee FY, Hwang SJ, et al. (1999). "Spider angiomas in patients with liver cirrhosis: role of alcoholism and impaired liver function". Scand. J. Gastroenterol. 34 (5): 520–3. doi:10.1080/003655299750026272. PMID 10423070. 
    6. ^ a b Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB (2004). "Pulmonary-Hepatic vascular Disorders (PHD)". Eur. Respir. J. 24 (5): 861–80. doi:10.1183/09031936.04.00010904. PMID 15516683. 
    7. ^ Kim MY, Choi H, Baik SK, et al. (April 2010). "Portal Hypertensive Gastropathy: Correlation with Portal Hypertension and Prognosis in Cirrhosis". Dig Dis Sci 55 (12): 3561–7. doi:10.1007/s10620-010-1221-6. ISBN 1062001012216. PMID 20407828. 
    8. ^ Alcohol-Induced Liver Disease; http://www.liverfoundation.org/abouttheliver/info/alcohol/
    9. ^ Iredale JP (2003). "Cirrhosis: new research provides a basis for rational and targeted treatments". BMJ 327 (7407): 143–7. doi:10.1136/bmj.327.7407.143. PMC 1126509. PMID 12869458. http://bmj.bmjjournals.com/cgi/content/full/327/7407/143. 
    10. ^ Grant, A; Neuberger J (1999). "Guidelines on the use of liver biopsy in clinical practice". Gut 45 (Suppl 4): 1–11. doi:10.1136/gut.45.2008.iv1. PMC 1766696. PMID 10485854. http://gut.bmj.com/cgi/content/full/45/suppl_4/IV1. "The main cause of mortality after percutaneous liver biopsy is intraperitoneal haemorrhage as shown in a retrospective Italian study of 68,000 percutaneous liver biopsies in which all six patients who died did so from intraperitoneal haemorrhage. Three of these patients had had a laparotomy, and all had either cirrhosis or malignant disease, both of which are risk factors for bleeding." 
    11. ^ Halfon P, Munteanu M, Poynard T (2008). "FibroTest-ActiTest as a non-invasive marker of liver fibrosis". Gastroenterol Clin Biol 32 (6): 22–39. doi:10.1016/S0399-8320(08)73991-5. PMID 18973844. 
    12. ^ Foucher J, Chanteloup E, Vergniol J, et al. (2006). "Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study". Gut 55 (3): 403–8. doi:10.1136/gut.2005.069153. PMC 1856085. PMID 16020491. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1856085. 
    13. ^ a b c Brenner, David; Richard A. Rippe (2003). "Pathogenesis of Hepatic Fibrosis". In Tadataka Yamada. Textbook of Gastroenterology. 2 (4th ed.). Lippincott Williams & Wilkins. ISBN 978-0781728614. 
    14. ^ Giallourakis CC, Rosenberg PM, Friedman LS (November 2002). "The liver in heart failure". Clin Liver Dis 6 (4): 947–67, viii–ix. doi:10.1016/S1089-3261(02)00056-9. PMID 12516201. 
    15. ^ Heathcote EJ (November 2003). "Primary biliary cirrhosis: historical perspective". Clin Liver Dis 7 (4): 735–40. doi:10.1016/S1089-3261(03)00098-9. PMID 14594128. 
    16. ^ Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973). "Transection of the oesophagus for bleeding oesophageal varices". Br J Surg 60 (8): 646–9. doi:10.1002/bjs.1800600817. PMID 4541913. 
    17. ^ Patch D, Armonis A, Sabin C, et al. (1999). "Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding". Gut 44 (2): 264–9. doi:10.1136/gut.44.2.264. PMC 1727391. PMID 9895388. http://gut.bmj.com/cgi/content/abstract/44/2/264. 
    18. ^ "E-medicine liver transplant outlook and survival rates". Emedicinehealth.com. 2009-06-09. http://www.emedicinehealth.com/liver_transplant/page11_em.htm. Retrieved 2009-09-06. 
    19. ^ Kamath PS, Kim WR (March 2007). "The model for end-stage liver disease (MELD)". Hepatology 45 (3): 797–805. doi:10.1002/hep.21563. PMID 17326206. 
    20. ^ a b Moore KP, Aithal GP (October 2006). "Guidelines on the management of ascites in cirrhosis". Gut 55 Suppl 6: vi1–12. doi:10.1136/gut.2006.099580. PMC 1860002. PMID 16966752. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1860002. 
    21. ^ Sundaram V, Shaikh OS (July 2009). "Hepatic encephalopathy: pathophysiology and emerging therapies". Med. Clin. North Am. 93 (4): 819–36, vii. doi:10.1016/j.mcna.2009.03.009. PMID 19577116. 
    22. ^ Ginés P, Arroyo V, Quintero E, et al. (1987). "Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study". Gastroenterology 93 (2): 234–41. PMID 3297907. 
    23. ^ "WHO Disease and injury country estimates". World Health Organization. 2009. http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.html. Retrieved Nov. 11, 2009. 
    24. ^ Anderson RN, Smith BL (2003). "Deaths: leading causes for 2001". National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 52 (9): 1–85. PMID 14626726. 
    25. ^ Sørensen HT, Thulstrup AM, Mellemkjar L, et al. (2003). "Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark". Journal of clinical epidemiology 56 (1): 88–93. doi:10.1016/S0895-4356(02)00531-0. PMID 12589875. 
    26. ^ Klatsky AL, Morton C, Udaltsova N, Friedman GD (2006). "Coffee, cirrhosis, and transaminase enzymes". Archives of Internal Medicine 166 (11): 1190–5. doi:10.1001/archinte.166.11.1190. PMID 16772246. 

    External links

    • Cirrhosis of the Liver at the National Digestive Diseases Information Clearinghouse (NDDIC). NIH Publication No. 04-1134, December 2003.

    Translations:

    Cirrhosis

    Top

    Dansk (Danish)
    n. - cirrose, skrumpning

    Nederlands (Dutch)
    leverziekte (cirrose)

    Français (French)
    n. - cirrhose

    Deutsch (German)
    n. - (Med.) Zirrhose, Schrumpfung

    Ελληνική (Greek)
    n. - (παθολ.) κίρρωση (του ήπατος)

    Italiano (Italian)
    cirrosi

    Português (Portuguese)
    n. - cirrose (f) (Med.)

    Русский (Russian)
    цирроз

    Español (Spanish)
    n. - cirrosis

    Svenska (Swedish)
    n. - cirrhos (med.)

    中文(简体)(Chinese (Simplified))
    硬化

    中文(繁體)(Chinese (Traditional))
    n. - 硬化

    한국어 (Korean)
    n. - 간장 등의 경화

    日本語 (Japanese)
    n. - 硬変

    العربيه (Arabic)
    ‏(الاسم) مرض تليف أو تشمع الكبد‏

    עברית (Hebrew)
    n. - ‮שחמת (מחלה), צמקת‬


     
     
    Related topics:
    hepatocirrhosis
    glissonian
    pseudocirrhosis

    Related answers:
    How is cirrhosis diagnosed? Read answer...
    Where does Cirrhosis occur? Read answer...
    What rhymes with cirrhosis? Read answer...

    Help us answer these:
    What is the symptoms of cirrhosis?
    Is cirrhosis irreversible?
    What is cirrhosis and how is it caused?

    Post a question - any question - to the WikiAnswers community:

     

    Copyrights:

    American Heritage Dictionary. The American Heritage® Dictionary of the English Language, Fourth Edition Copyright © 2007, 2000 by Houghton Mifflin Company. Updated in 2009. Published by Houghton Mifflin Company. All rights reserved.  Read more
    Britannica Concise Encyclopedia. Britannica Concise Encyclopedia. © 1994-2012 Encyclopædia Britannica, Inc. All rights reserved.  Read more
    McGraw-Hill Science & Technology Encyclopedia. McGraw-Hill Encyclopedia of Science and Technology. Copyright © 2005 by The McGraw-Hill Companies, Inc. All rights reserved.  Read more
    $copyright.smallImage.alttext Gale Encyclopedia of Public Health. Encyclopedia of Public Health. Copyright © 2002 by The Gale Group, Inc. All rights reserved.  Read more
    Columbia Encyclopedia. The Columbia Electronic Encyclopedia, Sixth Edition Copyright © 2012, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/ Read more
    Dictionary of Cultural Literacy: Health. The New Dictionary of Cultural Literacy, Third Edition Edited by E.D. Hirsch, Jr., Joseph F. Kett, and James Trefil. Copyright © 2002 by Houghton Mifflin Company. Published by Houghton Mifflin. All rights reserved.  Read more
    Saunders Veterinary Dictionary. Saunders Comprehensive Veterinary Dictionary 3rd Edition. Copyright © 2007 by D.C. Blood, V.P. Studdert and C.C. Gay, Elsevier. All rights reserved.  Read more
    Mosby's Dental Dictionary. Mosby's Dental Dictionary. Copyright © 2004 by Elsevier, Inc. All rights reserved.  Read more
    Random House Word Menu. © 2010 Write Brothers Inc. Word Menu is a registered trademark of the Estate of Stephen Glazier. Write Brothers Inc. All rights reserved.  Read more
     Rhymes. Oxford University Press. © 2006, 2007 All rights reserved.  Read more
    Wikipedia on Answers.com. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Cirrhosis Read more
    Translations. Copyright © 2007, WizCom Technologies Ltd. All rights reserved.  Read more

    Follow us
    Facebook Twitter
    YouTube